The global minimal residual disease market size is expected to reach USD 7,131.61 million by 2032, according to a new study by Polaris Market Research. The report “Minimal Residual Disease Market Share, Size, Trends, Industry Analysis Report, By Detection Target (Lymphoma, Leukemia, Solid Tumors, Others); By Test Technique; By End-Use; By Region; Segment Forecast, 2023-2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The increased prevalence of hematological malignancy and cancer, as well as rising healthcare spending, are expected to drive growth in the minimal residual disease sector throughout the forecast period. Additionally, rising consumer awareness of customized therapy and expanding investments in MRD research by public and private entities are both assisting in the market's expansion. Growth in the market is being slowed down by the heavy price of R&D activities.
The appropriate clinical evidence is used to successfully manage cancer therapies to prevent a residue of tumorous cells, and they are also tailored based on unique progression profiles in each individual. The necessity to consider a patient's unique genetic traits in order to provide effective therapy is being driven by several research studies. For example, in October 2022, Adaptive Biotechnologies, a commercial-stage biotechnology firm aiming to transform the genetics of the adaptive immune system into therapeutic solutions to detect and cure disease, announced a partnership with Epic to substantiate clonoSEQ Assay into Epic's full EMR system.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/minimal-residual-disease-market/request-for-sample
Additionally, the rising number of cancer patients and the rise in R&D spending are the two main factors driving the market. In addition, the industry is expanding due to the growing use of next-generation sequencing technologies. Additionally, the technological developments in diagnostics and therapies brought about by rising R&D expenditures are what's fueling the market's expansion.
Globally, the COVID-19 pandemic had an impact on healthcare systems and caused many healthcare facilities to stop providing routine care, putting at-risk cancer patients at serious risk. Although since the outbreak of the COVID-19 pandemic, steps have been taken to increase the number of covid patients admitted and decrease the number of non-covid patients admitted, resulting in treatment delays.
Minimal Residual Disease Market Report Highlights
Polaris Market Research has segmented the Minimal Residual Disease Market report based on detection target, test technique, end-user, and region:
Minimal Residual Disease, Detection Target Outlook (Revenue - USD Million, 2019 - 2032)
Minimal Residual Disease, Test Technique Outlook (Revenue - USD Million, 2019 - 2032)
Minimal Residual Disease, End-User Outlook (Revenue - USD Million, 2019 - 2032)
Minimal Residual Disease, Regional Outlook (Revenue - USD Million, 2019 - 2032)